Hillstream Biopharma (NASDAQ:CNTN) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Hillstream Biopharma (NASDAQ:CNTN) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings cut Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hillstream Biopharma Price Performance

NASDAQ CNTN opened at $2.19 on Friday. The firm has a market cap of $174.50 million, a price-to-earnings ratio of -4.38 and a beta of 1.45. The stock’s 50 day moving average price is $2.39. Hillstream Biopharma has a 1 year low of $1.75 and a 1 year high of $9.08.

Insider Activity

In related news, Director Gary S. Stetz sold 12,500 shares of Hillstream Biopharma stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $3.47, for a total transaction of $43,375.00. Following the sale, the director directly owned 134,175 shares of the company’s stock, valued at approximately $465,587.25. The trade was a 8.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 3.34% of the company’s stock.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.